Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00471094 | Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis | PHASE2 | COMPLETED | 831 | — | — | May 1, 2007 | Oct 1, 2007 | Feb 2, 2012 | 94 | United States |
| Arm | Type | Description |
|---|---|---|
| Ilaprazole 5 mg QD | EXPERIMENTAL | - |
| Ilaprazole 20 mg QD | EXPERIMENTAL | - |
| Ilaprazole 40 mg QD | EXPERIMENTAL | - |
| Lansoprazole 30 mg QD | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ilaprazole | DRUG | Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks. |
| Lansoprazole | DRUG | Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks. |
Inclusion Criteria: * Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D). Exclusion Criteria: * Evidence of uncontrolled, clinically significant systemic disease; acquired immunodeficiency syndrome (AIDs); a condit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tezepelumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | dupilumab, Dupilumab |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | PHASE2 | Vonoprazan |
| Eupraxia Pharmaceuticals, Inc. | EPRX | 1 | PHASE1 | EP-104GI |
| Sanofi SA Sponsored ADR | SNY | 1 | — | Dupilumab |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | — | Undisclosed |